- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispec
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032.
Two new studies of the potential neuroprotective agent nerinetide for patients with acute ischemic stroke have shown conflicting results, with suggestions of benefit when given very early in the prehospital setting.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2023 (GLOBE NEWSWIRE) HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM, HKEX: 13) today.